207 related articles for article (PubMed ID: 23409060)
1. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
[TBL] [Abstract][Full Text] [Related]
2. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M; Ferdani R; Shokeen M; Anderson CJ
Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
[TBL] [Abstract][Full Text] [Related]
6. PET Imaging of VLA-4 in a New BRAF
Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation of
Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
[TBL] [Abstract][Full Text] [Related]
8. First-in-Humans Evaluation of Safety and Dosimetry of
Laforest R; Ghai A; Fraum TJ; Oyama R; Frye J; Kaemmerer H; Gaehle G; Voller T; Mpoy C; Rogers BE; Fiala M; Shoghi KI; Achilefu S; Rettig M; Vij R; DiPersio JF; Schwarz S; Shokeen M; Dehdashti F
J Nucl Med; 2023 Feb; 64(2):320-328. PubMed ID: 36008121
[TBL] [Abstract][Full Text] [Related]
9. Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.
Mattila JT; Beaino W; Maiello P; Coleman MT; White AG; Scanga CA; Flynn JL; Anderson CJ
J Immunol; 2017 Jul; 199(2):806-815. PubMed ID: 28592427
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. A Metal-Free DOTA-Conjugated
Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Beaino W; Nedrow JR; Anderson CJ
Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
[TBL] [Abstract][Full Text] [Related]
13. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
[TBL] [Abstract][Full Text] [Related]
14. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice.
Perkins LA; Nyiranshuti L; Little-Ihrig L; Latoche JD; Day KE; Zhu Q; Tavakoli S; Sundd P; Novelli EM; Anderson CJ
Blood Adv; 2020 Sep; 4(17):4102-4112. PubMed ID: 32882004
[TBL] [Abstract][Full Text] [Related]
15. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
16. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.
Wadas TJ; Deng H; Sprague JE; Zheleznyak A; Weilbaecher KN; Anderson CJ
J Nucl Med; 2009 Nov; 50(11):1873-80. PubMed ID: 19875645
[TBL] [Abstract][Full Text] [Related]
17. Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
Haddad J; Latoche JD; Nigam S; Bellavia MC; Day KE; Zhu Q; Edwards WB; Anderson CJ; Tavakoli S
J Nucl Med; 2021 Feb; 62(2):280-286. PubMed ID: 32680928
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Al
Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
[TBL] [Abstract][Full Text] [Related]
19. Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.
Long Y; Lv X; Song X; Shao F; Ji H; Zhang Y; Qiao P; Liu Q; Xia X; Lei P; Gai Y; Lan X
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4156-4170. PubMed ID: 35790537
[TBL] [Abstract][Full Text] [Related]
20. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.
Guo Y; Ferdani R; Anderson CJ
Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
